EU regulator recommends suspension of drugs over Indian data

LONDON, Jan 23 (Reuters) - Europe's drug regulator said on
Friday it had recommended the suspension of a number of drugs
which were approved on the basis of clinical studies conducted
at GVK Biosciences in Hyderabad, India.

The European Medicines Agency said the recommendation was
based on findings from an inspection that raised concerns about
how GVK conducted studies at the Hyderabad site on behalf of the
pharmaceutical companies.

The move follows a similar decision from state regulators in
France, Germany, Belgium and Luxembourg in December to suspend
the marketing approval of 25 generic drugs due to concerns over
the quality of data from clinical trials conducted by the Indian
firm.